selected publications
-
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2013
Academic Article
GET IT
Times cited: 37 -
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 26 -
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
British journal of haematology.
2007
Academic Article
GET IT
Times cited: 73